Contact Number: 301-402-4164
Contact Email: timothy.lyden@nih.gov
The NINDS IGNITE (Innovation Grants to Nurture Initial Translational Efforts) program is a multi-component suite of funding opportunities that is meant to facilitate the discovery and development of early-stage therapeutic biotechnology products. The following three funding opportunities have upcoming receipt dates in June 2016:
- PAR-15-070: Assay Development and Therapeutic Agent Identification and Characterization to Support Therapeutic Discovery (R21/R33), next receipt date is June 16
- PAR-15-071: Pharmacodynamics and In vivo Efficacy Studies for Small Molecules and Biologics/Biotechnology Products (R21/R33), next receipt date is June 16
- RFA-NS-16-013: Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate the Discovery of Neurotherapeutics (R21/R33), next receipt date is June 21
The program serves as a feeder program to the later-stage therapy development programs launched by NINDS, namely the Cooperative Research to Enable and Advance Translational Enterprises (CREATE) for Biologics and Blueprint Neurotherapeutics (BPN) programs. An interactive Q&A session will be held for interested applicants on Wednesday, May 11, 2016 from 2:30-3:30 PM EST. All potential IGNITE applicants are encouraged to participate. Investigators can find information about these funding opportunities at: https://www.ninds.nih.gov/Current-Research/Research-Funded-NINDS/Translational-Research/Funding-Programs-Researchers/IGNITE
If you would like to log in for this meeting, please RSVP to timothy.lyden@nih.gov. You can also submit questions before the meeting to timothy.Lyden@nih.gov. While you can listen to the meeting by phone, all questions will need to be submitted online.
https://nih.webex.com/nih/j.php?MTID=mc1936c22037110a829c3c55565ac2011